UZH-Logo

Maintenance Infos

The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats


Furrer, D; Kaufmann, K; Tschuor, F; Reusch, C E; Lutz, T A (2010). The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats. Veterinary Journal, 183(3):355-357.

Abstract

Glucagon-like peptide-1 (GLP-1) analogues and inhibitors of its degrading enzyme, dipeptidyl peptidase IV (DPPIV), are interesting therapy options in human diabetics because they increase insulin secretion and reduce postprandial glucagon secretion. Given the similar pathophysiology of human type 2 and feline diabetes mellitus, this study investigated whether the DPPIV inhibitor NVP-DPP728 reduces plasma glucagon levels in cats. Intravenous glucose tolerance tests (ivGTT; 0.5g/kg glucose after 12h fasting) and a meal response test (test meal of 50% of average daily food intake, offered after 24h fasting) were performed in healthy experimental cats. NVP-DPP728 (0.5-2.5mg/kg IV or SC) significantly reduced glucagon output in all tests and increased insulin output in the ivGTT. Follow-up studies will investigate the potential usefulness as therapy in diabetic cats.

Abstract

Glucagon-like peptide-1 (GLP-1) analogues and inhibitors of its degrading enzyme, dipeptidyl peptidase IV (DPPIV), are interesting therapy options in human diabetics because they increase insulin secretion and reduce postprandial glucagon secretion. Given the similar pathophysiology of human type 2 and feline diabetes mellitus, this study investigated whether the DPPIV inhibitor NVP-DPP728 reduces plasma glucagon levels in cats. Intravenous glucose tolerance tests (ivGTT; 0.5g/kg glucose after 12h fasting) and a meal response test (test meal of 50% of average daily food intake, offered after 24h fasting) were performed in healthy experimental cats. NVP-DPP728 (0.5-2.5mg/kg IV or SC) significantly reduced glucagon output in all tests and increased insulin output in the ivGTT. Follow-up studies will investigate the potential usefulness as therapy in diabetic cats.

Citations

11 citations in Web of Science®
11 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

258 downloads since deposited on 13 Mar 2009
19 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Institute of Veterinary Physiology
04 Faculty of Medicine > Center for Integrative Human Physiology
05 Vetsuisse Faculty > Veterinary Clinic > Department of Small Animals
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Language:English
Date:5 March 2010
Deposited On:13 Mar 2009 09:36
Last Modified:05 Apr 2016 12:52
Publisher:Elsevier
ISSN:1090-0233
Publisher DOI:https://doi.org/10.1016/j.tvjl.2008.11.017
PubMed ID:19128990

Download

[img]
Preview
Content: Accepted Version
Filetype: PDF
Size: 1MB
View at publisher
[img]
Filetype: PDF - Registered users only
Size: 1MB

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations